Loss of Betaglycan Expression in Ovarian Cancer: Role in Motility and Invasion
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The transforming growth factor-β (TGF-β) superfamily members, TGF-β, activin, and inhibin, all have prominent roles in regulating normal ovarian function. Betaglycan, or the type III TGF-β receptor, is a coreceptor that regulates TGF-β, activin, and inhibin signaling. Here, we show that betaglycan expression is frequently decreased or lost in epithelial derived ovarian cancer at both the mRNA and protein level, with the degree of loss correlating with tumor grade. Treatment of ovarian cancer cell lines with the methyltransferase inhibitor 5-aza-2-deoxycytidine and the histone deacetylase inhibitor trichostatin A resulted in significant synergistic induction of betaglycan message levels and increased betaglycan protein expression, indicating that epigenetic silencing may play a role in the loss of betaglycan expression observed in ovarian cancer. Although restoring betaglycan expression in Ovca429 ovarian cancer cells is not sufficient to restore TGF-β–mediated inhibition of proliferation, betaglycan significantly inhibits ovarian cancer cell motility and invasiveness. Furthermore, betaglycan specifically enhances the antimigratory effects of inhibin and the ability of inhibin to repress matrix metalloproteinase levels in these cells. These results show, for the first time, epigenetic regulation of betaglycan expression in ovarian cancer, and a novel role for betaglycan in regulating ovarian cancer motility and invasiveness. [Cancer Res 2007;67(11):5231–8]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Activation of Signalling by the Activin Receptor Complex
Attisano, L., Wrana, J. L., Montalvo, E., & Massagué, J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.3.1066 · Cited by 316
Cited by
The emerging role of TGF-β superfamily coreceptors in cancer
Bernabeu, C., Lopez-Novoa, J. M., & Quintanilla, M. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.07.003 · Cited by 254
TGF-β family co-receptor function and signaling
Nickel, J., Ten Dijke, P., & Mueller, T. D. (2018) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx126 · Cited by 198
HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts
Ko, S. Y., Barengo, N., Ladanyi, A., Lee, J.-S., Marini, F., Lengyel, E., & Naora, H. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62229 · Cited by 132
“However, CAFs might also be activated by other mechanisms, since not all EOCs express HOXA9 .”
InfluentialHill, C. R., Sanchez, N. S., Love, J. D., Arrieta, J. A., Hong, C. C., Brown, C. B., Austin, A. F., & Barnett, J. V. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2011.12.022 · Cited by 40
Metadata
- Authors
- Hempel, N., How, T., Dong, M., Murphy, S. K., Fields, T. A., & Blobe, G. C.
- Venue
- Cancer Research
- Published
- 2007-06-01
- Volume
- 67
- Issue
- 11
- Pages
- 5231-5238
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2170563954
- Cited by
- 123
- References
- 2
- FWCI
- 4.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Loss of Betaglycan Expression in Ovarian Cancer: Role in Motility and Invasion. https://app.cochat.ai/papers/10.1158/0008-5472.can-07-0035
- The paper
- Hempel, N., How, T., Dong, M., Murphy, S. K., Fields, T. A., & Blobe, G. C. (2007). Loss of Betaglycan Expression in Ovarian Cancer: Role in Motility and Invasion. Cancer Research. https://doi.org/10.1158/0008-5472.can-07-0035
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.